New cancer screening available for veterans VA Pittsburgh Healthcare

Pittsburgh, PA – Veterans will soon have the chance to test a new tool for cancer screening – all through bleeding.

The Veterans Affairs Division and the Veterans Health Foundation have partnered with GRAIL, LLC to provide veterans with access to GRAIL’s groundbreaking Early Detection of Multiple Cancer (MCED) blood test. GRAIL will make its Galleri MCED test available to 10,000 veterans on approximately 10 sites over the next three years. The VA Pittsburgh Healthcare System will pilot the program.

Blood screening tests will be offered as part of the REFLECTION real-world clinical trial. The study will review whether Galleri, along with other standard cancer screenings, can detect cancer at an early stage when treatment is most likely to be successful.

Nationwide, 1.2 million veterans who have used VA health care since the beginning of fiscal 2021 have been diagnosed with cancer. That number includes 14% of veterans treated at the Pittsburgh VA over the same period.

“Cancer is a leading cause of illness and death for veterans,” said VA Pittsburgh pulmonologist Dr. Charles Atwood, director of lung cancer screening and lead researcher in the REFLECTION study. “Our partnership with GRAIL and the Galleri test will help VA expand its efforts to detect cancer early.”

Atwood said tests for early detection of many cancers will be provided to veterans in addition to current recommended screenings. The goal, he said, is to improve early diagnoses and results.

Early detection of cancer is known to improve outcomes, but most are detected in the late stages, as only five species have recommended screening – breast, cervix, colon, lung and prostate. In a clinical trial, the Galleri test demonstrated the ability to detect more than 50 cancers, more than 45 of which do not have recommended screening tests today, with a low false-positive rate of less than 1%. The test also determines the origin of the cancer with high accuracy.

Veterans interested in the Galleri test and the REFLECTION study can ask their primary care provider for more information on how to participate.

“We are excited to partner with VA and US veterans on this important assessment of the Galleri test, along with recommended standard screenings, for its potential to transform early detection into this at-risk population,” said Bob Ragusa, CEO of GRAAL. . “The partnership will help veterans gain access to the REFLECTION registry study and receive a test that we hope will lead to more cancer diagnoses at an earlier stage when treatment is more likely to be successful.


The VA Pittsburgh Health System (VAPHS) is one of the largest and most progressive VA health systems in the nation. More than 4,000 employees serve nearly 80,000 veterans each year, providing a range of services from comprehensive transplant medicine to routine first aid. VAPHS is a leader in providing virtual care through telehealth technology; a research and training center with 130 researchers and $ 14.8 million in funding for fiscal 2021; and a provider of state-of-the-art healthcare training to some 1,500 students per year. VAPHS provides care at medical centers in the Auckland neighborhood of Pittsburgh and the nearby town of O’Hara, both in Pennsylvania and at five outpatient clinics in Belmont County, Ohio, and Beaver, Fayette, Washington and Westmoreland counties in Pennsylvania. An additional care center is expected to open in 2023 in Monroeville, Pennsylvania. Veterans can call 412-360-6162 to check eligibility or enrollment. Stay up to date with, Facebook and Twitter.

Founded in 1991, the Veterans Health Foundation (VHF), a former Pittsburgh Veterans Research Foundation, facilitates and supports part-time research and educational activities by collaborating with the VA Pittsburgh Healthcare System, private companies, government agencies, foundations and academic institutions. Title 38 USC ┬ž7361-7366 authorizes VA Medical Centers to establish non-profit research and education corporations to accept and administer private and non-VA federal funds in support of VA research and education missions. The intention of the Congress to enable these corporations is to provide the VA with facilities with a flexible funding mechanism for conducting research as well as training staff and patients.

GRAIL is a healthcare company whose mission is to detect cancer early when it can be cured. GRAIL is focused on alleviating the global cancer burden by developing pioneering technology for the early detection and identification of many deadly cancers. The company is using the power of next-generation sequencing, population-based clinical trials and state-of-the-art computer science and data science to improve scientific understanding of cancer biology and develop its blood for early detection of many cancers. test. GRAIL is headquartered in Menlo Park, California, with locations in Washington, DC, North Carolina and the United Kingdom. GRAIL, LLC, is a wholly owned subsidiary of Illumina, Inc. (NASDAQ: ILMN). For more information, please visit

The earlier the cancer is detected, the greater the chance of successful results. Galleri’s early detection test for many cancers can detect cancer in more than 50 cancers, as determined by the US Joint Committee on Staging Cancer, through routine blood sampling. When a cancer signal is detected, the Galleri test predicts the origin of the cancer signal or where the cancer is located in the body with high accuracy to help guide the next steps toward diagnosis. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer tests, such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. It is intended for use in people at increased risk of cancer, such as those aged 50 or over. For more information on Galleri, visit

Important safety information for Galleri
The Galleri test is recommended for use in adults at increased risk of cancer, such as those aged 50 years or older. The Galleri test may not detect a cancer signal in all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is designed to detect cancer signals and predict where the cancer signal is located in the body. Galleri is not recommended for use in pregnant women, 21 years of age or younger or undergoing active cancer treatment.

The results should be interpreted by the healthcare provider in the context of medical history, clinical signs and symptoms. The result of the “Cancer signal not detected” test does not rule out cancer. The result of the “Cancer Signal Test” test requires a confirmatory diagnostic evaluation through medically established procedures (eg imaging) to confirm cancer.

If the cancer is not confirmed by further testing, it may mean that the cancer is not present or the test is insufficient to detect cancer, including due to the location of the cancer in a different part of the body. False-positive (cancer signal detected when cancer is not present) and false-negative (cancer signal that is not detected when cancer is present) test results are obtained. Only Rx.

Laboratory / test information
The GRAIL Clinical Laboratory is certified under the 1988 Clinical Laboratory Amendments (CLIA) and is accredited by the College of American Pathologists. The Galleri test has been developed and its performance characteristics have been determined by GRAIL. The Galleri test is not approved or approved by the US Food and Drug Administration. The GRAIL Clinical Laboratory is regulated by the CLIA to perform highly complex tests. The Galleri test is intended for clinical purposes.

Leave a Comment

Your email address will not be published.